Uniphar
Uniphar plc, headquartered in Ireland (IE), is a leading player in the pharmaceutical and healthcare industry, specialising in the distribution of medicines and healthcare products. Founded in 1998, Uniphar has established a strong presence across Europe, particularly in Ireland and the UK, and has expanded its operations into various international markets. The company offers a diverse range of services, including supply chain management, clinical trial support, and commercialisation solutions for pharmaceutical companies. Uniphar's unique approach combines innovative technology with deep industry expertise, ensuring efficient delivery and compliance in a complex regulatory environment. Recognised for its commitment to quality and customer service, Uniphar has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector. With a focus on enhancing patient outcomes, Uniphar continues to drive growth and innovation within the industry.
DitchCarbon Score
How does Uniphar's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Uniphar's score of 35 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Uniphar's reported carbon emissions
In 2023, Uniphar reported total greenhouse gas emissions of approximately 5,903,780 kg CO2e, comprising 2,980,450 kg CO2e from Scope 1 and 2,923,330 kg CO2e from Scope 2. This marks a slight increase from 2022, where total emissions were about 5,873,260 kg CO2e, with Scope 1 emissions at 2,854,420 kg CO2e and Scope 2 emissions at 3,018,840 kg CO2e. Uniphar has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, using 2019 as the base year. Additionally, the company plans for 73.5% of its suppliers, based on emissions from purchased goods and services, to have science-based targets by 2027. These targets align with the necessary reductions to limit global warming to 1.5°C, demonstrating Uniphar's commitment to sustainability within the healthcare sector. As of now, Uniphar has not disclosed any Scope 3 emissions data, focusing primarily on its direct and indirect emissions from operations. The company continues to monitor and report its emissions, striving for transparency and accountability in its climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 3,954,880 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,794,840 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Uniphar is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
